PBH Prestige Consumer Healthcare Inc.
Debt Financing ·
Prestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026.
The company's subsidiary drew $95,000,000 on July 1, 2026. The 8-K also notes a $400,000,000 private offering of senior unsecured notes due 2034 whose pricing a July 6, 2026 press release announced.
Prestige Consumer Healthcare (NYSE: PBH) completed the Breathe Right purchase for $1.045 billion in cash and entered a Term Loan Credit Agreement. It also raised its asset-based revolver commitments to $225 million.
Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of brand name over-the-counter health and personal care products in North America, Australia and certain other international markets. It conducts operations in two reportable segments, North American OTC Healthcare and International OTC Healthcare, and its fiscal year ends March 31. Its major brands include Chloraseptic sore throat products, Monistat vaginal anti-fungal treatments, Fleet adult enemas and suppositories, Gaviscon upset stomach remedies, Dramamine motion sickness relief, Compound W wart removal and Nix lice treatments. Its International segment includes Fess nasal saline sprays and Hydralyte oral rehydration products, with the Fess and Hydralyte data for the Australian market. Major brands accounted for approximately 83.5% of total revenues for 2026. The company has grown its portfolio through acquisitions and organic growth, and sells through mass merchandisers, drug and drug wholesale, food, dollar, convenience and club stores and e-commerce channels.
| Product or program | What it is | Stage |
|---|---|---|
| Chloraseptic | Sore throat sprays and lozenges | |
| Monistat | Vaginal anti-fungal treatment for yeast infections | |
| Fleet | Adult enemas and suppositories | |
| Gaviscon | Upset stomach remedy that forms a protective foam barrier | |
| Dramamine | Motion sickness relief | |
| Compound W | Wart removal treatment |
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Net income (loss) | $190.3 million | $214.6 million |
| Cash from operations | $257.6 million | $251.5 million |
| Cash and equivalents | $63.9 million | $97.9 million |
Our latest story on this, dated Jul 6, 2026: "Prestige Consumer Healthcare draws $95.0 million term loan to fund LaCorium acquisition". The story links the filing or release it is based on. Read the story.
Prestige Consumer Healthcare Inc. trades under the ticker PBH on NYSE.
Prestige Consumer Healthcare Inc. is listed on NYSE.
The SEC Central Index Key (CIK) for Prestige Consumer Healthcare Inc. is 1295947. Its filings are on SEC EDGAR.
47,374,522 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Prestige Consumer Healthcare Inc. under United States.
Our directory classifies Prestige Consumer Healthcare Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Prestige Consumer Healthcare Inc. is US74112D1019.
aibio.space lists Prestige Consumer Healthcare Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of brand name over-the-counter health and personal care products in North America, Australia and certain other international markets. It conducts operations in two reportable segments, North American OTC Healthcare and International OTC Healthcare, and its fiscal year ends March 31.
Chloraseptic: Sore throat sprays and lozenges
Monistat: Vaginal anti-fungal treatment for yeast infections
Prestige Consumer Healthcare Inc. reported net income of $190.3 million for the fiscal year ended Mar 31, 2026, and generated $257.6 million of cash from operations, per its annual report to the SEC.
$89.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Prestige Consumer Healthcare, dated Jul 15, 2026: "Prestige Brands sells $400.0 million of 6.250% senior notes due 2034". Prestige Brands, a subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due 2034. The 8-K names no placement agent, underwriter or advisor and does not say how the proceeds will be used. The parent's annual report says Walmart and Amazon were its only customers above 10% of gross revenues during 2026. Source.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio